NT Mobile Menu


Samuel Pleasure, MD, PhD

Samuel Pleasure, MD, PhD

Samuel Pleasure, MD, PhD, is Professor of Neurology and Neuroscience at UCSF School of Medicine. He attended Penn for his MD and PhD (Neuroscience) and trained clinically at UCSF. His scientific interests are in brain development and the role of autoimmunity in causing CNS disease. He has numerous scientific publications and is an active clinician seeing patients in the MS clinic as well as attending at San Francisco General Hospital.

Posts by Author

Observations over the last few years have indicated that an inciting event of narcolepsy may be infection with influenza or vaccination with particular influenza vaccines.

Our blogger discusses a recent study investigating the likelihood of head trauma in older patients leading to the onset of Parkinson disease and the implications of the findings.

What is the function of continued adult myelination in the normal undiseased brain? A recent study sheds remarkable light on this process and its importance.

Potential approaches to devising strategies that may allow amelioration of this disease are revealed in a recent study. But questions remain.

A switch to a second-line drug in a patient receiving first-line therapies likely will be effective at decreasing disease activity.

The ultimate cause is found in only about half of patients, so improved understanding of the prognostic and diagnostic features is of high priority.

The risk of progressive multifocal leukoencephalopathy in patients receiving Tysabri for MS is a concern about this otherwise extremely effective therapy.

What happens before the demyelinating lesions of MS appear? Does smoking confer protection against Parkinson disease? How is NMDA receptor-associated disease reversed? Here are 4 fine papers from 2014 that set out to answer these questions.

Patients with juvenile myoclonic epilepsy appear to have modest cognitive defects and imaging abnormalities early on that are unlikely to be associated with anti-epileptic therapy. This is a clear departure from traditional teaching.

Serum testing for NMDAR and other autoantibodies is fraught with pitfalls, and careful clinical consideration is important.


By clicking Accept, you agree to become a member of the UBM Medica Community.